CHM and choroideremia: In addition to Luxturna, three clinical trials advanced to Phase III collectively, including antisense oligonucleotides-based QR-110 for LCA10, AAV5-RPRG gene-drug for XLRP and AAV2-REP1 for choroideremia (Table 1).